Society of Interventional Radiology Position Statement on Chemoembolization of Hepatic Malignancies

Journal of Vascular and Interventional Radiology

Volumn 20, Issue 7 SUPPL., 2009, Pages

  Brown, Daniel B ^a   Geschwind, Jean Francois H ^b   Soulen, Michael C ^c   Millward, Steven F ^e   Sacks, David ^d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d READING HOSPITAL AND MEDICAL CENTER   (United States)

^e Peterborough Regional Health Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; COLLAGEN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GELATIN SPONGE; IODINATED POPPYSEED OIL; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; POLYVINYL ALCOHOL; TAMOXIFEN; VINBLASTINE;

ARTICLE; BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COLORECTAL CANCER; HEPATIC ARTERY; HOSPITALIZATION; HUMAN; INFARCTION; INTERVENTIONAL RADIOLOGY; LEIOMYOSARCOMA; LIVER ABSCESS; LIVER CARCINOMA; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER METASTASIS; LIVER TRANSPLANTATION; MEDICAL SOCIETY; MELANOMA; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; TUMOR REGRESSION;

EID: 67649756658     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvir.2009.04.015     Document Type: Article

References (66)

1. El-Serag H.B. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35S (2002) 72-78
2. Wong J.B., McQuillan G.M., McHutchison J.G., et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 90 (2000) 1562-1569
3. Jemal A., Murray T., Ward E., et al. Cancer Statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
4. Nakamura H., Hashimoto T., Oi H., et al. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 170 (1989) 783-786
5. Sasaki Y., Imaoka S., Kasugai H., et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 60 (1987) 1194-1203
6. Konno T. Targeting cancer chemo-therapeutic agents by use of lipiodol contrast medium. Cancer 66 (1990) 1897-1903
7. Egawa H., Maki A., Mori K., et al. Effects of intra-arterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in lipiodol on experimental liver tumor in rats. J Surg Oncol 44 (1990) 109-114
8. Daniels J.R., Sternlicht M., and Daniels A.M. Collagen chemoembolization: pharmacokinetics and tissue tolerance of cisdiamminedichloroplatinum(II) in porcine liver and rabbit kidney. Cancer Res 48 (1988) 2446-2450
9. Kruskal J.B., Hlatky L., Hahnfeldt P., et al. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol 4 (1993) 741-747
10. Ramsey D.E., Kernagis L.Y., Soulen M.C., et al. Chemoembolization of hepato-cellular carcinoma. J Vasc Interv Radiol 13 suppl (2002) S211-S221
11. Li X., Feng G.S., Zheng C.S., et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 10 (2004) 2878-2882
12. Liao X., Yi J., Li X., et al. Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization. J Huazhong Univ Sci Technol Med Sci 23 (2003) 280-282
13. Camma C., Schepis F., Orlando A., et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224 (2002) 47-54
14. Kanematsu T., Furui J., Yanaga K., et al. A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985-2000. Surgery 131 (2002) 153-158
15. Yanaga K. Current status of hepatic resection for hepatocellular carcinoma. J Gastroenterol 39 (2004) 919-926
16. Island E.R., Pomposelli J., Pomfret E.A., et al. Twenty-year experience with liver transplantation for hepatocellular carcinoma. Arch Surg 140 (2005) 353-358
17. Befeler A.S., Hayashi P.H., and Di Bisceglie A.M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 128 (2005) 1752-1764
18. Lai C.L., Wu P.C., Chan G.C., et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma: a prospective randomized trial. Cancer 62 (1988) 479-483
19. Lee H.S., Kim K.M., Yoon J.H., et al. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 20 (2002) 4459-4465
20. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37 (2003) 429-442
21. Solomon B., Soulen M.C., Baum R.A., et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol 10 (1999) 793-798
22. Brown D.B., Fundakowski C.E., and LiskerMelman M. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 15 (2004) 1209-1218
23. Chevret S., Trinchet J.C., Mathieu D., et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 31 (1999) 133-141
24. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332 (1995) 1256-1261
25. Pelletier G., Roche A., Ink O., et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11 (1990) 181-184
26. Bruix J., Llovet J.M., Castells A., et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27 (1998) 1578-1583
27. Geschwind J.F., Ramsey D.E., Choti M.A., et al. Chemoembolization of hepato-cellular carcinoma: results of a meta-analysis. Am J Clin Oncol 26 (2003) 344-349
28. Trevisani F., De Notariis S., and Rossi C. Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies?. J Clin Gastroenterol 32 (2001) 383-389
29. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
30. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepato-cellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
31. Bronowicki J.P., Vetter D., Dumas F., et al. Transcatheter oily chemoembolization for hepatocellular carcinoma: a 4-year study of 127 French patients. Cancer 74 (1994) 16-24
32. Barone M., Ettorre G.C., Ladisa R., et al. Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma. Hepatogastroenterology 50 (2003) 183-187
33. Wiesner R., Edwards E., Freeman R., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124 (2003) 91-96
34. Fisher R.A., Maluf D., Cotterell A.H., et al. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant 18 (2004) 502-512
35. Duszak R. Vascular occlusion: can we push radiofrequency ablation into new size frontiers?. Radiology 231 (2004) 291-292
36. Yamakado K., Nakatsuka A., Ohmori S., et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol 13 (2002) 1225-1232
37. Rossi S., Garbagnati F., Lencioni R., et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 217 (2000) 119-126
38. Maluccio M., Covey A.M., Gandhi R., et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol 16 (2005) 955-961
39. Bramhall S.R., Gur U., Coldham C., et al. Liver resection for colorectal metastases. Ann R Coll Surg Engl 85 (2003) 334-339
40. Chafai N., Chan C.L., Bokey E.L., et al. What factors influence survival in patients with unresected synchronous liver metastases after resection of colorectal cancer?. Colorectal Dis 7 (2005) 176-181
41. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
42. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
43. Abramson R.G., Rosen M.P., Perry L.J., et al. Cost-effectiveness of hepatic arterial chemoembolization for colorectal liver metastases refractory to systemic chemotherapy. Radiology 216 (2000) 485-491
44. Lang E.K., and Brown C.L. Colorectal metastases to the liver: selective chemoembolization. Radiology 189 (1993) 417-422
45. Sanz-Altamira P.M., Spence L.D., Huber-man M.S., et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum 40 (1997) 770-775
46. Tellez C., Benson A.B., Lyster M.T., et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 82 (1998) 1250-1259
47. Soulen M.C. Chemoembolization of hepatic malignancies. Semin Intervent Radiol 14 (1997) 305-311
48. Salman H.S., Cynamon J., Jagust M., et al. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer 2 (2002) 173-179
49. Vogl T.J., Mack M.G., Balzer J.O., et al. Liver metastases: neoadjuvant down-sizing with transarterial chemoembolization before laser-induced thermo-therapy. Radiology 229 (2003) 457-464
50. Kath R., Hayungs J., Bornfeld N., et al. Prognosis and treatment of disseminated uveal melanoma. Cancer 72 (1993) 2219-2223
51. Gragoudas E.S., Egan K.M., Seddon J.M., et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 98 (1991) 383-389
52. Bedikian A.Y., Legha S.S., Mavligit G., et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 76 (1995) 1665-1670
53. Mavligit G.M., Charnsangavej C., Carrasco C.H., et al. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 260 (1988) 974-976
54. Stokes K., Stuart K., and Clouse M. Hepatic arterial chemoembolization for meta-static endocrine tumors. J Vasc Interv Radiol 4 (1993) 341-345
55. Therasse E., Breittmayer F., Roche A., et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 189 (1993) 541-547
56. Brown K.T., Koh B.Y., Brody L.A., et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 10 (1999) 397-403
57. Gupta S., Yao J.C., Ahrar K., et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 9 (2003) 261-267
58. Mavligit G.M., Zukwiski A.A., Ellis L.M., et al. Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer 75 (1995) 2083-2088
59. Rajan D.K., Soulen M.C., Clark T.W.I., et al. Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-c, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol 12 (2001) 187-193
60. Burger I., Hong K., Schulick R., et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 16 (2005) 353-361
61. Giroux M.F., Baum R.A., and Soulen M.C. Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol 15 (2004) 289-291
62. Mavligit G.M., Estrov Z., and Ayala A. Carcinoma of the stomach metastatic to the liver that progressed after hepatic arterial infusion of cisplatin plus 5-floxuri-dine, and then dramatically regressed after chemoembolization based on positive chromogranin staining. Am J Clin Oncol 22 (1999) 320-322
63. Andras C., Szucs Farkas Z., Csiki Z., et al. Clinical evaluation of local lipiodol chemoembolization therapy in primary and secondary hepatic tumors. Orv Hetil 141 (2000) 1773-1777
64. Caturelli E., Siena D.A., Fusilli S., et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. Radiology 215 (2000) 123-128
65. Kim W., Clark T.W.I., Baum R.A., et al. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 12 (2001) 965-968
66. Sakamoto I., Aso N., Nagaoki K., et al. Complications associated with trans-catheter arterial embolization for hepatic tumors. Radiographics 18 (1998) 605-619